SCHEMBL18017374

SCHEMBL18017374

C[C@H](c1ccc(Cl)nc1)[C@H]1CC[C@@H](Cc2ccc(C(=O)O)cc2)N1C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
ADRB1 P08588 3/20 0.37
ADRB3 P13945 3/20 0.37
CETP P11597 3/20 0.35
NAPRT Q6XQN6 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34
HDAC1 Q13547 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33
KCNK3 O14649 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18017375 1.00 RXRA (0.37) RXRARXRBADRB1ADRB3CETP
SCHEMBL16620041 0.91 ADRB1 (0.38) RXRARXRBADRB1ADRB3CETP
SCHEMBL18017379 0.91 ADRB1 (0.38) RXRARXRBADRB1ADRB3CETP
SCHEMBL16620038 0.91 ADRB1 (0.38) RXRARXRBADRB1ADRB3CETP
SCHEMBL18017402 0.90 RXRA (0.35) RXRARXRBCETPHDAC1NPC1
SCHEMBL18017393 0.90 HDAC1 (0.36) RXRARXRBCETPHDAC1PTGER4
SCHEMBL18210794 0.90 PTGER4 (0.35) RXRARXRBCETPHDAC1PTGER4
SCHEMBL18017382 0.88 RXRA (0.38) RXRARXRBNPC1ALDH1A1MAPT
SCHEMBL18017400 0.87 CETP (0.34) RXRARXRBCETPHDAC1
SCHEMBL18017427 0.87 ADRB1 (0.34) RXRARXRBADRB1ADRB3CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 RXRA 1400/4885RXRB 1020/4885ADRB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.